JINYU(SH:600201)2022-08-29 16:00Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a 15% increase compared to the same period last year[15]. - The net profit attributable to shareholders reached 100 million CNY, showing a growth of 20% year-on-year[15]. - The company's operating revenue for the first half of the year was ¥641,850,484.38, representing a decrease of 23.63% compared to the same period last year[21]. - Net profit attributable to shareholders was ¥104,942,906.60, down 59.32% year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥108,102,309.94, a decrease of 57.02% compared to the previous year[21]. - The basic earnings per share for the period was ¥0.09, down 60.87% from ¥0.23 in the same period last year[21]. - The diluted earnings per share also stood at ¥0.09, showing a 60.87% decrease compared to the previous year[21]. - The total comprehensive income for the period amounted to CNY 258,150,823.52, reflecting a positive performance compared to the previous period[161]. Market and Product Development - User data indicates an increase in active customers by 30%, totaling 1 million users by the end of June 2022[15]. - The company plans to launch two new vaccine products in Q3 2022, aiming to capture a 10% market share in the animal health sector[15]. - Future guidance estimates a revenue growth of 25% for the full year 2022, driven by new product launches and market expansion[15]. - The company focuses on the development of animal vaccines, maintaining a leading market share in foot-and-mouth disease vaccines, with a steady increase in sales revenue from non-foot-and-mouth disease vaccines[29]. - The company is advancing the development of multi-valent vaccines to address customer needs and establish competitive barriers in the market[45]. Research and Development - Research and development expenses increased by 10% to 50 million CNY, focusing on innovative vaccine technologies[15]. - The company's R&D investment reached 76.75 million yuan, accounting for 11.96% of operating revenue, focusing on the development of African swine fever vaccines and other innovative products[45]. - The company established an integrated R&D platform for African swine fever vaccines, with multiple technical pathways progressing steadily, including single, double, and multi-gene deletion vaccines[45]. - The company received 2 invention patents and had 11 invention patent applications accepted during the reporting period, indicating a strong focus on innovation[48]. Financial Position and Cash Flow - The company has maintained a strong cash position with 200 million CNY in cash reserves, ensuring liquidity for upcoming projects[15]. - The net cash flow from operating activities was ¥40,003,276.03, reflecting a decline of 50.02% year-on-year[21]. - The total cash and cash equivalents decreased from ¥1,334,156,187.45 to ¥1,183,775,261.83, representing a decline of approximately 11.3%[123]. - The company reported cash inflows from investment activities totaling CNY 165,329.12 million, compared to CNY 391,528.60 million in the previous year, a decrease of 57.8%[145]. Environmental Compliance and Sustainability - The company has implemented measures to ensure compliance with environmental standards, including the collection and treatment of waste gas[77]. - The wastewater treatment station at Jin Yu Bao Ling has a design capacity of 1,000 m³/d, utilizing a "pulse anaerobic + MBR aerobic" treatment process[82]. - Jin Yu Bao Ling invested CNY 92.34 million in environmental protection measures during the construction of its biotechnology industrial park[80]. - The company achieved zero environmental accidents and received no administrative penalties from higher authorities during the reporting period[90]. Corporate Governance and Management - The company held its 11th Board of Directors and Supervisory Board elections on May 31, 2022, with Zhang Chongyu elected as Chairman and Zhang Jing as Vice Chairman and President[68]. - The company has appointed Li Rong as Vice President during the recent management changes[68]. - The company has seen a complete turnover in its supervisory board, with all members being newly elected[68]. Shareholder Information - The company repurchased a total of 19,782,600 shares, representing 1.76% of the total share capital, through centralized bidding transactions as of June 30, 2022[108]. - The total number of shares increased from 1,126,202,241 to 1,126,202,241 after the share repurchase, with limited sale condition shares rising to 25,615,615[107]. - The number of shareholders reached 77,279 by the end of the reporting period[112].